Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

被引：4
|
作者：
Kelley, Robin Kate
Rimassa, Lorenza
Ryoo, Baek-Yeol
Park, Joong-Won
Blanc, Jean-Frederic
Chan, Stephen Lam
Dadduzio, Vincenzo
Yau, Thomas Cheung
Sen, Suvajit
Markby, David W.
Kaldate, Rajesh
El-Khoueiry, Anthony B.
Cheng, Ann-Lii
Meyer, Tim
Abou-Alfa, Ghassan K.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Humanitas Clin & Res Ctr, Rozzano, Italy
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Natl Canc Ctr Korea, Goyang Si, South Korea
[5] Grp Hosp St Andre, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[6] Chinese Univ Hong Kong, State Key Lab Oncol South China, Dept Clin Oncol, Hong Kong, Peoples R China
[7] IRCCS, Ist Oncol Veneto, Padua, Italy
[8] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[9] Exelixis Inc, Alameda, CA USA
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[13] UCL, Canc Inst, London, England
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.423
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
423
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Outcomes in patients who had received sorafenib as the only prior systemic therapy in the Phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Strasser, S. I.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 21 - 22
  • [32] Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis
    Waldschmidt, D.
    Teufel, M.
    Koechert, K.
    Meinhardt, G.
    Bruix, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 281 - 282
  • [33] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik-Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han Chong
    Gorbunova, Vera
    Eskens, Ferry
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El Nowiem, Saied
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [34] Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.
    Teufel, Michael
    Kochert, Karl
    Meinhardt, Gerold
    Bruix, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Changes in alpha-fetoprotein (AFP) and systemic therapy outcomes in advanced hepatocellular carcinoma (HCC): A multicenter retrospective analysis.
    Bocobo, Andrea Grace
    Bracci, Paige M.
    Parks, Anna
    Hannan, Lindsay Marie
    Bauer, Kelly
    Goyal, Lipika
    Gordan, John Dozier
    Venook, Alan P.
    Harris, William Proctor
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [36] Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)
    Cheng, A.
    Kang, Y.
    Lin, D.
    Park, J.
    Kudo, M.
    Qin, S.
    Omata, M.
    Lowenthal, S. W. Pitman
    Lanzalone, S.
    Yang, L.
    Lechuga, M.
    Raymond, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial
    Trojan, J.
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    Cicin, I.
    Bolondi, L.
    Kluempen, H. J.
    Chan, S. L.
    Dadduzio, V.
    Milwee, S.
    Dubey, S.
    Kelley, R. K.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 243 - 243
  • [38] Association of Adverse Events (AES) with Efficiacy Outcomes for Cabozantinib (C) in Patients (PTS) with Advanced Hepatocellular Carcinoma (AHCC) in the Phase 3 Celestial Trial
    Waidmann, Oliver
    Abou-Alfa, G. K.
    Meker, T.
    Cheng, A. L.
    Cicin, I.
    Bolondi, L.
    Klumpem, H. J.
    Chan, S. L.
    Dadduzio, V.
    Milwee, S.
    Dubey, S.
    Kelley, R. K.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 60 - 60
  • [39] Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
    Cheng, A.
    Kang, Y.
    Chen, Z.
    Tsao, C.
    Qin, S.
    Kim, J.
    Burock, K.
    Zou, J.
    Voliotis, D.
    Guan, Z. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
    El-Khoueiry, A.
    Meyer, T.
    Cheng, A.
    Rimassa, L.
    Sen, S.
    Milwee, S.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S220 - S220
12345